Identifying Appropriate Candidates for Cellular Therapy in Multiple Myeloma

In this segment, Dr. Ajay Nooka engages the panel in a discussion on how to identify appropriate candidates for cellular therapy in relapsed and refractory multiple myeloma. Dr. Noopur Raje and Dr. Surbhi Sidana share their perspectives on the clinical, biologic, and functional factors that guide this decision. The conversation highlights the importance of disease characteristics such as tempo of progression, prior treatment exposure, and depth of prior response, as well as patient-related factors including performance status and comorbidities. The panel also discusses how timing plays a critical role, particularly in determining when to transition from conventional systemic therapies to a cell-based approach. Emphasis is placed on selecting patients who are most likely to benefit while maintaining safety and feasibility. This segment underscores the nuanced and individualized approach required when considering cellular therapies in the management of multiple myeloma.